Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Industries is projected to achieve significant sales growth for its innovative products, with anticipated 2026 revenues of $785 million for Ajovy, reflecting a year-on-year increase of 17%, and $278 million for Uzedy, marking a substantial 45% rise. The company's robust performance is further supported by strong market penetration and projected revenue growth for Austedo, with expectations for peak sales to exceed $3 billion due to an under-treated patient population. Teva's management is also confident in achieving an enhanced EBITDA margin driven by a transition to higher-value products and targeted cost savings of $700 million by 2027, indicating a positive trajectory for both cash flows and overall financial health.

Bears say

Teva Pharmaceutical Industries faces significant challenges that contribute to a negative outlook, highlighted by a sequential decline expected in 1Q26 and anticipated year-over-year declines in 4Q26 due to pricing pressures approaching IRA implementation. The company's fourth-quarter results in 2025 reflected a normalized topline miss, exacerbated by a one-time milestone payment and a decline in generics revenue, which fell short of estimates by 3%, driven by an 11% decrease in US prescriptions. Additionally, risks related to regulatory uncertainty, litigation, and the execution of its pipeline pose potential threats to future financial performance, overshadowing projected debt paydowns and decreases in annual financial expenses.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.